IIT Guwahati harnesses clay sedimentation to identify and measure Coronavirus
The findings of this research have been published in the prestigious peer-reviewed journal, Applied Clay Science, in a paper co-authored by Prof. T V Bharat, Department of Civil Engineering, and Prof. Sachin Kumar, Department of Biosciences and Bioengineering, along with research scholars Dr Himanshu Yadav and Deepa Mehta at
IIT Guwahati
.
Posing a threat to human lives globally, COVID-19 pandemic revealed a critical gap in how viral infections are detected and tracked. Current methods, such as Polymerase Chain Reaction (PCR), are highly sensitive but time-consuming and require heavy equipment.
Similarly, the antigen testing is fast but lacks accuracy, while antibody testing is used after the infection has occurred, highlighting limitations at various levels. Additionally, many of these methods are not practical in resource-limited settings or during large-scale outbreaks.
To address these gaps, Prof. T V Bharat, Dept. of Civil Engineering, IIT Guwahati, along with his research team has used Bentonite clay, a clay well known for its ability to absorb pollutants and heavy metals due to its unique chemical structure in collaboration with Prof. Sachin Kumar, Department of Biosciences and Bioengineering.
Previous studies have shown that clay particles can bind with viruses and bacteriophages, making it a promising material for virus detection.
The research team focused on how Bentonite clay interacts with virus particles in a salt environment.
The research team found that a Coronavirus surrogate and Infectious Bronchitis Virus (IBV) bind to the negatively charged clay surfaces at a controlled room temperature and a neutral pH of 7.
Speaking about the findings of the research, Prof. T V Bharat said, "Imagine a world where detecting viruses is as simple as watching sand settle in water. That is the breakthrough we have achieved! Our new method uses clay to quickly identify and measure viruses, like the coronavirus. By observing how the clay settles in a solution, we can determine if a virus is present and how much of it there is. This innovative approach offers a faster, more affordable, and accurate alternative to current methods, paving the way for better disease monitoring and treatment strategies, especially during pandemics, this study is in continuation with our recent studies published in prestigious journals like Langmuir in developing exclusive biomedical waste facilities for disposing pathogenic waste sponsored by Department of Science and Technology, Government of India."
The research team validated their findings using established virus-detection methods, including plaque assay for a coronavirus surrogate and RT-PCR for IBV.
The developed technique produced accurate results in comparison to the standard detection methods, reinforcing its reliability.
Notably, the method can be extended to detect other viruses such as the Newcastle Disease Virus (NDV), which affects poultry and causes major losses in the farming industry.
This development holds great promise for improving how viral outbreaks are monitored and controlled, especially in regions where expensive lab equipment and trained personnel are not readily available. With further refinement, the method could be adapted for use in field kits or simple laboratory setups, making virus detection more accessible and efficient in future public health emergencies.
As the next step, the research team is planning to collaborate with industry partners with medical facilities for
clinical trials for SARS-Cov-2
and other viruses.
By partnering with industry, the research team hopes to leverage the resources and expertise necessary to conduct robust clinical trials and ultimately contribute to the global effort to combat viral infections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
44 minutes ago
- Time of India
NIT Rourkela decodes sugar molecules, protein complex to boost bone regeneration tech
New Delhi: Researchers at the National Institute of Technology (NIT), Rourkela have uncovered how natural sugar-like molecules in the human body can alter the behaviour of Bone Morphogenetic Protein-2 (BMP-2), a protein responsible for bone formation and repair, according to officials. Published in the prestigious journal Biochemistry, the findings of this research can be used for advanced treatments in bone and cartilage regeneration, improved implants and more effective protein-based medicines. According to Harekrushna Sahoo, Associate Professor, NIT, Rourkela, proteins carry out various functions in the human body -- from building tissues and supporting chemical reactions to acting as signals between cells. However, for the best productivity, they need to be folded or unfolded into precise three-dimensional shapes. Understanding why and how proteins unfold is a major goal in biology, with implications for medicine, biotechnology and drug delivery. "In this context, BMP-2 plays a crucial role in forming bones and cartilage, healing injuries and guiding stem cells to become bone-forming cells. However, in the human body, this protein interacts with different Glycosaminoglycans (GAGs), special sugar-like molecules found in connective tissues and joint fluids," Sahoo said. The team observed that BMP-2 unfolded faster in the presence of Sulfated Hyaluronic Acid (SHA), a type of GAG, compared to regular Hyaluronic Acid or without additives. The researchers found that SHA binds directly to BMP-2 protein, gently altering its structure and making it unfold in a more controlled manner. "BMP-2 is a critical protein in humans that plays a fundamental role in osteogenesis and bone regeneration . Our study reveals how specific GAG-BMP-2 interactions influence unfolding dynamics and structural stability. These insights allow scaffold designs to actively preserve BMP-2's functional conformation, prolong bioactivity, lower dosage needs and reduce side effects. "Furthermore, the work offers a mechanistic basis for tailoring GAG functional group modifications to modulate protein structure and activity, guiding next-generation pharmaceutical formulation," he said.
Time of India
an hour ago
- Time of India
How Goa managed to tame rabies: Inside state's drive that vaccinated 63,000 dogs in 30 days
PANAJI: Since Sept 2017, Goa has largely eliminated human rabies cases, earning a 'rabies-controlled' status in 2021 after three consecutive years without a single death from the virus. Tired of too many ads? go ad free now The streak was broken by one case in 2023, but there were no fatalities in 2024 and none so far this year. 'Even if a single stray dog misses vaccination and sterilisation, it can lead to a litter of eight or nine puppies that are at risk,' said Nilkanth Harlankar, the state's minister for animal husbandry and veterinary services. The story began in 2014 when the threat of rabies in Goa was all too real: 17 people succumbed to the virus that year. There was no reliable data on the dog population — stray or pet — nor any formal record of dog mortality. Then came Mission Rabies, a fledgling NGO with a pilot surveillance project that uncovered a grim truth: of the 45 suspected animal cases they investigated, 39 tested positive for rabies. Instead of being daunted, they doubled down, aiming to vaccinate 50,000 dogs in just 30 days. By the end of the month, over 500 vets from 16 different countries joined forces with local teams and managed to exceed the target: they vaccinated 63,000 dogs. This momentum translated into policy the very next year. In 2015, the thenCM Manohar Parrikar signed an MoU with Mission Rabies, launching a full-fledged vaccination and sterilisation drive across the state. Following this, Goa had 24-hour rabies surveillance, an emergency hotline, rapid response teams, and field volunteers fanning out to every taluka, vaccinating and sterilising dogs, and assisting bite victims. Tired of too many ads? go ad free now From Sept 2017, human rabies cases in Goa virtually disappeared. But the Covid-19 lockdown brought fresh challenges. As tourism halted and markets closed, hungry stray dogs from neighbouring states wandered into Goa. Mission Rabies suspects this migration led to a spike in animal cases in border talukas. Goa's borders with Maharashtra and Karnataka remain points of vulnerability, with rabies cases still detected in talukas like Bicholim, Pernem, Sattari, and Canacona. 'We are vaccinating stray dogs in border talukas on a warfooting,' said Harlankar. In June 2021, it was made mandatory for visitors bringing pets into Goa to declare their animals and share vaccination records via the anti-rabies hotline to prevent cross-border transmission.
Time of India
2 hours ago
- Time of India
Why US budget cuts could derail future mRNA vaccine progress
mRNA vaccines are credited with helping to end the COVID-19 pandemic and save millions of lives. Since then, researchers have been developing the technology to prevent a variety of infectious diseases and cancer. But experts warn this progress has been severely impacted after US health secretary Robert F Kennedy announced cuts to mRNA technology research. In total, the US health department will cancel contracts and withdraw $500 million (€427 million) of research funding, it announced on August 8. The announcement was the latest in a series of anti-science policies brought in by President Trump's second term in office, including a political take-over of federal research grants and withdrawing from the World Health Organization. What does this mean for the future of mRNA vaccine development? We take a look. mRNA vaccines have a long history of safety and efficacy mRNA vaccines were first tested in mice to vaccinate against flu in the 1990s, then first tested in humans in 2013 to vaccinate against rabies . It was thanks to these decades of research and testing that mRNA vaccine technology was ready and safe during the COVID-19 pandemic. Kennedy has been a longtime critic of the technology, saying in a video posted to social media platforms that mRNA programs are "troubled'. "We're prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don't collapse when viruses mutate," Kennedy said in the video. What other types of vaccine are in development? There are many types of vaccines in development that have different methods of helping the body to fight a virus. Each technology has advantages and limitations which depend on the disease, the target population, and practical considerations like production speed and costs. Vaccine technology platforms include live (but weakened) and deactivated "whole" pathogen vaccines. The polio vaccine is available in both forms, for example. There are also toxoid-based vaccines, which use inactivated bacterial toxins. Then there are viral vector vaccines, which train the immune system by introducing tiny viral pathogenic fragments into the body. DNA-based therapies are also being considered as another way to provide an accurate target for a human immune response. Luka Cicin-Sain, a viral immunologist at Germany's Helmholtz Centre for Infection Research, is leading the development of a respiratory syncytial virus (RSV) vaccine. The RSV vaccine is a viral vector product, which uses a low-risk mouse virus to deliver the RSV spike protein to the human immune system. Though still being tested, Cicin-Sain is hopeful that his platform will provide long-lasting immunity against RSV with a single immunization dose. Are other types of vaccines as good as mRNA vaccines? Despite the promise these other vaccine technologies have shown, they haven't had the same impact as their mRNA cousin. That's because the benefit of using mRNA technology as vaccines is the ability to quickly adapt their use for new pathogens. "Once you know the structure of the virus, the genetics of the virus, then you can produce a vaccine extremely rapidly," said Penny Ward, a pharmaceutical physician at Kings College London, UK. In some cases, mRNA vaccines can be more effective at training the body's immune response to a pathogen. "We don't seem to produce the same immune response to a DNA vaccine as we have to a [m]RNA vaccine," said Ward. Will a loss for mRNA research be a gain for other vaccines? There is no guarantee the $500 million funding will flow to other vaccine research. Kennedy is a longtime vaccine critic — he has fired the panel that makes vaccine recommendations and shared anti-vax sentiment, including during a measles outbreak in the US in May. Cicin-Sain worries that defunding one branch of vaccine science hinders overall progress in the research field. "I'm not saying that mRNA vaccines can solve everything, but why deny yourself a tool in your toolkit?" Cicin-Sain said. Kennedy's funding cuts will slow down RNA technology development, Cicin-Sain said, and drive American scientists to compete for funding outside the US, diminishing ongoing vaccine science. Will others step in to fund mRNA vaccine research ? While other private and philanthropical research funds do exist to fund mRNA vaccine technologies, it's unlikely they can fill the $500 million gap left by the Trump administration's cuts. There's also no guarantee other national governments will step in to fill the US void. "The funding in Europe has been stagnant," said Cicin-Sain. "And there are not so many [private] investors out there who think that vaccines are the best way to put their VC [venture capital] at work," he added. Ward highlighted another problem with cuts to publicly funded vaccine research — governments who fund vaccine research get first access to successful products, which is why Brits were among the first to get the Oxford-AstraZeneca vaccine. "Government funding secures access for countries that are part funders for those products," Ward told DW. If private funders step in to fund mRNA vaccine research, it could reduce people's access to those vaccines at an affordable price. "If progress is to be made, and there's no source of government funding, the industry will fund [research] if they believe there's a market, but that will be reflected in the price of the eventual product,' Ward said. "No matter how you slice or dice, the net effects are going to be negative," Cicin-Sain said.
